Effect of patient choice and hospital competition on service configuration and technology adoption within cancer surgery: a national, population-based study

Ajay Aggarwal(King's College London), Jan van der Meulen(London School of Hygiene & Tropical Medicine), Richard Sullivan(Precision Spine (United States)), Arnie Purushotham(King's College London), Malcolm D. Mason(Royal Marsden Hospital), Daniel Lewis(The Huntington Library, Art Museum, and Botanical Gardens)
The Lancet Oncology
October 5, 2017
10.1016/s1470-2045(17)30572-7
Cited by 102

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study
|The Lancet Oncology|2020|1.9k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
The Lancet Commission on diagnostics: transforming access to diagnostics
|The Lancet|2021|442